Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy (FMTB Brij)  

The goal of this randomized, prospective, interventional clinical trial is to evaluate the use of Brijjit® in reducing the incidence of hypertrophic scarring in individuals undergoing gender-affirming bilateral double incision mastectomies at a single-institution, single-surgeon site (Esther A. Kim, MD). Patients will serve as a self-control (one side of the …

Accepts healthy volunteers
  • 0 views
  • 04 Dec, 2025
  • 2 locations
Cisplatin+Pembrolizumab+RT in Vulvar Cancer

This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: Cisplatin (standard of care drug) Pembrolizumab (investigational drug) Radiation Therapy (standard of care intervention)

cisplatin
international normalized ratio (inr)
primary tumor
conjugated bilirubin
carcinoma
  • 0 views
  • 19 Feb, 2024
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2

Embedded within the Master Study are individual drug substudies. Investigational Drug Sub-study A: Brigatinib

investigational drug
meningiomatosis
brigatinib
experimental drug
ependymoma
  • 0 views
  • 19 Feb, 2024
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

metastatic castration-resistant prostate cancer
diphosphonates
castration-resistant prostate cancer
progressive disease
metastasis
  • 0 views
  • 19 Feb, 2024
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.

epithelioid sarcoma
rhabdoid tumor
immunohistochemistry
serum lipase
neutrophil count
  • 0 views
  • 19 Feb, 2024
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

ipatasertib
colony stimulating factor
adjuvant therapy
platelet count
sentinel lymph node biopsy
  • 0 views
  • 19 Feb, 2024
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

waldenstrom's macroglobulinemia
ibrutinib
plasmapheresis
venetoclax
neutrophil count
  • 0 views
  • 19 Feb, 2024
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

cns disease
triple negative breast neoplasms
neuropathy
immunomodulators
keytruda
  • 8 views
  • 19 Feb, 2024
A Study to Explore Personalized Treatment for Patients with Recurrent Gynecological Malignancies Based on MTB (RWS-MTB)

Attending physicians will determine the final treatment plan, integrating multidisciplinary recommendations with patient preferences, comorbidity considerations, drug toxicity assessments, insurance coverage for off-label medications, and the availability of investigational drug trials. This arm aims to observe and evaluate the clinical efficacy of personalized treatment plans developed through molecular tumor profiling …

  • 0 views
  • 17 Jan, 2025